Hexarelin Research: The Synthetic Hexapeptide Behind GHS-R and CD36 Studies

What published research reports on hexarelin: its structure, growth hormone secretagogue receptor activity, CD36 binding, cardiac models and desensitization findings.

Share

Hexarelin is a small synthetic peptide from the growth hormone releasing peptide (GHRP) family. It was developed in the early 1990s as a more stable relative of GHRP-6, and it went on to become one of the most studied tools for probing two different receptor systems: the growth hormone secretagogue receptor (GHS-R1a, later known as the ghrelin receptor) and the scavenger receptor CD36. This overview summarises what the published literature reports about hexarelin, what remains uncertain, and why it still appears in laboratory work. It is written for researchers and does not discuss use in people.

Structure and origin

Hexarelin (also called examorelin) is a hexapeptide with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. It differs from GHRP-6 mainly by the 2-methyl group on the D-tryptophan at position two. That small change was intended to make the peptide more resistant to breakdown and more potent at its receptor.

The first full pharmacology paper appeared in 1994. Deghenghi and colleagues reported in Life Sciences that hexarelin released growth hormone in both infant and adult rats, and compared its activity with earlier GHRPs. Follow-up rat work by Torsello and colleagues in 1996, published in the European Journal of Endocrinology, examined the mechanism of that GH-releasing activity in more detail, including its relationship to the hypothalamic hormone GHRH.

The receptor story: from orphan peptide to ghrelin

When hexarelin was first described, nobody knew which receptor it acted on. The GHRPs were synthetic molecules in search of a target. That changed in 1996, when Howard and colleagues reported in Science the cloning of a G protein-coupled receptor in the pituitary and hypothalamus that responded to these synthetic secretagogues. It became known as GHS-R1a.

Three years later, Kojima and colleagues published in Nature the discovery of ghrelin, an acylated peptide from the stomach that turned out to be the natural ligand for that receptor. In other words, hexarelin and its relatives were used to help find the receptor before its natural hormone was known. This is one reason the GHRPs remain historically important in endocrinology research, and why the GHRP-6 story is closely linked to hexarelin's.

Growth hormone release in human and animal studies

A large part of the early hexarelin literature measured growth hormone responses. Ghigo and colleagues reported in the Journal of Clinical Endocrinology & Metabolism in 1994 that hexarelin raised circulating growth hormone after intravenous, subcutaneous, intranasal and oral administration, with the different routes giving very different potencies. The same year, Laron and colleagues described GH-releasing activity after intranasal administration of the hexapeptide in Clinical Endocrinology.

Other 1994 work looked at how hexarelin interacts with the rest of the axis. Arvat and colleagues reported that arginine and GHRH could restore a blunted hexarelin GH response in elderly subjects, pointing to an age-related component in the response. Guillaume and colleagues showed in Endocrinology that the hexapeptide stimulated GHRH secretion in sheep, evidence that hexarelin acts at the hypothalamus as well as the pituitary.

These studies are reported here as published physiology findings. They describe measurements in research settings and are not statements about outcomes in people outside those studies.

Desensitization: an important caveat

One recurring theme in the hexarelin literature is desensitization. Repeated exposure tends to blunt the growth hormone response over time. Rahim and colleagues addressed this directly in a paper titled "Does desensitization to hexarelin occur?" in Growth Hormone & IGF Research in 1998. The question matters for anyone designing repeated-dosing experiments, because a declining response can be mistaken for a change in the preparation rather than a receptor-level adaptation.

The CD36 branch: cardiac research

Hexarelin became interesting for a second reason that has little to do with growth hormone. Researchers found that it binds CD36, a scavenger receptor expressed in heart and vascular tissue, and that some of its cardiovascular effects in animals are independent of growth hormone release.

Locatelli and colleagues reported in Endocrinology in 1999 that hexarelin had growth hormone-independent cardioprotective effects in the rat. Bodart and colleagues followed in Circulation Research in 2002 with evidence that CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. A later review by Mao and colleagues in the Journal of Geriatric Cardiology in 2014 summarised the cardiovascular action of hexarelin across this body of work, and the same group reported experiments in ghrelin knockout mice after myocardial infarction in Endocrinology in 2013, which helped separate the ghrelin-receptor and CD36 pathways.

This two-receptor behaviour is the single most useful thing to know about hexarelin as a research tool: the same molecule reports on two different systems, and experiments have to be designed carefully to tell them apart.

What the evidence does and does not establish

Most of the hexarelin literature is animal work or short human physiology studies from the 1990s and early 2000s. The GH-releasing activity is well documented across species. The CD36-mediated cardiac effects are supported by several independent groups but remain an area of active, unsettled research rather than settled fact. Long-term data are limited, and desensitization complicates interpretation of repeated exposure.

For laboratories, that means hexarelin is best treated as a mechanistic probe with a well-characterised short-term pharmacology and a less certain long-term picture.

Handling notes

Like other small peptides, hexarelin is typically supplied lyophilized and is sensitive to moisture and repeated freeze-thaw cycles. General guidance on storage and reconstitution is covered in our storage guide and reconstitution guide. Purity and identity should be confirmed on a certificate of analysis before experimental work; see how to read a COA.

Frequently asked questions

What is hexarelin? A synthetic hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) in the growth hormone releasing peptide family, used in research as a growth hormone secretagogue and a CD36 ligand.

How does hexarelin relate to ghrelin? Hexarelin acts at the growth hormone secretagogue receptor GHS-R1a. That receptor was cloned in 1996, and ghrelin was later identified in 1999 as its natural ligand.

Why is CD36 mentioned in hexarelin research? Some of hexarelin's cardiovascular effects in animal models appear to be mediated by CD36 rather than the ghrelin receptor, and are independent of growth hormone release.

References

  • Deghenghi R, Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences. 1994;54(18):1321-1328. doi:10.1016/0024-3205(94)00510-9.
  • Ghigo E, Arvat E, Gianotti L, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. Journal of Clinical Endocrinology & Metabolism. 1994;78(3):693-698. doi:10.1210/jcem.78.3.8126144.
  • Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin). Clinical Endocrinology (Oxford). 1994;41(4):539-541. doi:10.1111/j.1365-2265.1994.tb02589.x.
  • Arvat E, Gianotti L, Grottoli S, et al. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1994;79(5):1440-1443. doi:10.1210/jcem.79.5.7962341.
  • Guillaume V, Magnan E, Cataldi M, et al. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology. 1994;135(3):1073-1076. doi:10.1210/endo.135.3.7915227.
  • Torsello A, Luoni M, Grilli R, et al. Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat. European Journal of Endocrinology. 1996;135(4):481-488. doi:10.1530/eje.0.1350481.
  • Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974.
  • Rahim A, O'Neill PA, Shalet SM. Does desensitization to hexarelin occur? Growth Hormone & IGF Research. 1998;8 Suppl B:141-143. doi:10.1016/s1096-6374(98)80039-7.
  • Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi:10.1038/45230.
  • Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031. doi:10.1210/endo.140.9.6948.
  • Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circulation Research. 2002;90(8):844-849. doi:10.1161/01.res.0000016164.02525.b4.
  • Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. Journal of Geriatric Cardiology. 2014;11(3):253-258. doi:10.11909/j.issn.1671-5411.2014.03.007.
  • Mao Y, Tokudome T, Kishimoto I, et al. Hexarelin treatment in male ghrelin knockout mice after myocardial infarction. Endocrinology. 2013;154(10):3847-3854. doi:10.1210/en.2013-1291.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.